Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Teste para aumentar a frequência da FEP

1 de outubro de 2026 atualizado por: William Smith, University of Pennsylvania

Incentivos financeiros para aumentar a frequência ao tratamento no primeiro episódio psicótico: um estudo piloto adaptativo não randomizado

Individuals with first-episode psychosis (FEP) are at high-risk for several poor functional and clinical outcomes, including suicide. Coordinated Specialty Care (CSC) is a multidisciplinary, team-based intervention known to improve such outcomes, including suicide risk. However, 30-50% of patients disengage from CSC, thereby limiting its impact. This pilot study will develop and test feasibility of a behavioral change program that uses moderate financial incentives to encourage treatment engagement in 2 CSC programs. A single-arm of 80 patient-participants at these two clinics will be recruited to assess feasibility and acceptability from patient perspectives. Additionally,15 clinicians at these two clinics will be recruited to assess feasibility and acceptability from clinician perspectives, and 50 clinicians from peer clinics not involved in the intervention will be recruited to assess scalability of the intervention. The trial will feature an three-month period for recruitment and baseline data collection and will subsequently feature three intervention periods (3 months each) where modifications to the interventions will be tested (each informed by the feasibility and acceptability findings of the prior period) with the aim of sequentially improving it.

Visão geral do estudo

Status

Ativo, não recrutando

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

145

Estágio

  • Fase inicial 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • North Carolina
      • Raleigh, North Carolina, Estados Unidos, 27608
        • University of North Carolina at Chapel Hill (ENCOMPASS Program)
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19123
        • PEACE Program, Horizon House, Inc.
      • Philadephia, Pennsylvania, Estados Unidos, 19104
        • University of Pennsylvania

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. For all participants, age ≥ 18 years old.
  2. For intervention trial and patient feasibility and acceptability measurement: Patients with first-episode psychosis, enrolled in Coordinated Specialty Care at the Psychosis Education, Assessment, Care and Empowerment (PEACE) clinic and Psychosis Evaluation and Recovery Center (PERC).
  3. For clinician feasibility and acceptability measurement at intervention sites: Clinicians working at PEACE and PERC where the intervention will be piloted.
  4. For clinician implementation facilitator and barrier assessment at other Connection LHS sites to assess for scalability: Clinicians in Connection LHS who work at sites other than PEACE and PERC.Participants must sign the informed consent form

Exclusion Criteria:

  1. For intervention trial and patient feasibility and acceptability measurement: Expectation of leaving coordinated specialty care programing within 6 months (which will exclude all of the PI's patient panel) and/or intellectual disability of sufficient degree that the patient's primary psychiatrist expects to compromise capacity to consent to this research and/or psychosis secondary to another medical condition (which may not share the same motivational features that are otherwise understood about the primary psychiatric conditions with psychosis).
  2. For clinician feasibility and acceptability measurement at intervention sites: Study investigators who work at these clinics will be excluded from participation in the feasibility and acceptability study component given their role in the trial planning and execution.
  3. For clinician implementation facilitator and barrier assessment at other Connection LHS sites to assess for scalability: none.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Acceptability of intervention measure (AIM)
Prazo: Change at 8 months

The AIM is a 4-item scale measuring acceptability. Each item is scored 1-5 with 5 indicating greater acceptability. Minimum score is 4; maximum is 20.

Change at 8 months
Acceptability of intervention measure (AIM)
Prazo: Change at 6 months

The AIM is a 4-item scale measuring acceptability. Each item is scored 1-5 with 5 indicating greater acceptability. Minimum score is 4; maximum is 20.

Change at 6 months
Acceptability of intervention measure (AIM)
Prazo: Change at 4 months

The AIM is a 4-item scale measuring acceptability. Each item is scored 1-5 with 5 indicating greater acceptability. Minimum score is 4; maximum is 20.

Change at 4 months
Feasibility of intervention measure (FIM)
Prazo: Change at 8 months

The FIM is a 4-item scale measuring feasibility. Each item is scored 1-5 with 5 indicating greater feasibility. Minimum score is 4; maximum is 20.

Change at 8 months
Feasibility of intervention measure (FIM)
Prazo: Change at 6 months

The FIM is a 4-item scale measuring feasibility. Each item is scored 1-5 with 5 indicating greater feasibility. Minimum score is 4; maximum is 20.

Change at 6 months
Feasibility of intervention measure (FIM)
Prazo: Change at 4 months

The FIM is a 4-item scale measuring feasibility. Each item is scored 1-5 with 5 indicating greater feasibility. Minimum score is 4; maximum is 20.

Change at 4 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Implementation Survey Response
Prazo: Change at 8 months

Implementation survey. Results will be used to optimize intervention from implementation perspective.

Change at 8 months
Implementation Survey Response
Prazo: Change at 6 months

Implementation survey. Results will be used to optimize intervention from implementation perspective.

Change at 6 months
Implementation Survey Response
Prazo: Change at 4 months

Implementation survey. Results will be used to optimize intervention from implementation perspective.

Change at 4 months
Motivation Survey Response
Prazo: Change at 8 months

Motivation survey. Results will be used to optimize intervention from motivation perspective.

Change at 8 months
Motivation Survey Response
Prazo: Change at 6 months

Motivation survey. Results will be used to optimize intervention from motivation perspective.

Change at 6 months
Motivation Survey Response
Prazo: Change at 4 months

Motivation survey. Results will be used to optimize intervention from motivation perspective.

Change at 4 months
Ethical Concern Survey Response
Prazo: Change at 8 months

Ethical concern survey. Results will be used to optimize intervention from ethical acceptability perspective.

Change at 8 months
Ethical Concern Survey Response
Prazo: Change at 6 months

Ethical concern survey. Results will be used to optimize intervention from ethical acceptability perspective.

Change at 6 months
Ethical Concern Survey Response
Prazo: Change at 4 months

Ethical concern survey. Results will be used to optimize intervention from ethical acceptability perspective.

Change at 4 months

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
attrition
Prazo: Change at 8 months

rate of attrition

Change at 8 months
attrition
Prazo: Change at 6 months

rate of attrition

Change at 6 months
attrition
Prazo: Change at 4 months

rate of attrition

Change at 4 months
psychotic symptomology
Prazo: Change at 8 months

Compass-10. The Compass-10 is a self-report scale that measures multiple symptoms associated with psychosis, including mood symptoms. It consists of 10-items, each scored 0-6 with a minimum score of 0 and a maximum of 60. A higher score indicates greater symptomology.

Change at 8 months
psychotic symptomology
Prazo: Change at 6 months

Compass-10. The Compass-10 is a self-report scale that measures multiple symptoms associated with psychosis, including mood symptoms. It consists of 10-items, each scored 0-6 with a minimum score of 0 and a maximum of 60. A higher score indicates greater symptomology.

Change at 6 months
psychotic symptomology
Prazo: Change at 4 months

Compass-10. The Compass-10 is a self-report scale that measures multiple symptoms associated with psychosis, including mood symptoms. It consists of 10-items, each scored 0-6 with a minimum score of 0 and a maximum of 60. A higher score indicates greater symptomology.

Change at 4 months
psychotic symptomology
Prazo: Change at 8 months

modified-Colorado Symptom Index. The modified-Colorado Symptom Index is a 14-item, clinician-rated scale with items ranked 0-4. Total minimum score = 0. Total maximum score = 56. A higher score indicates greater symptomology.

Change at 8 months
psychotic symptomology
Prazo: Change at 6 months

modified-Colorado Symptom Index. The modified-Colorado Symptom Index is a 14-item, clinician-rated scale with items ranked 0-4. Total minimum score = 0. Total maximum score = 56. A higher score indicates greater symptomology.

Change at 6 months
psychotic symptomology
Prazo: Change at 4 months

modified-Colorado Symptom Index. The modified-Colorado Symptom Index is a 14-item, clinician-rated scale with items ranked 0-4. Total minimum score = 0. Total maximum score = 56. A higher score indicates greater symptomology.

Change at 4 months
depression
Prazo: Change at 8 months

abbreviated version of the Beck Depression Inventory-II (BDI-II) that has been previously validated (scale, min=0, max=21, higher mean score indicates more severe depressive symptomology)

Change at 8 months
depression
Prazo: Change at 6 months

abbreviated version of the Beck Depression Inventory-II (BDI-II) that has been previously validated (scale, min=0, max=21, higher mean score indicates more severe depressive symptomology)

Change at 6 months
depression
Prazo: Change at 4 months

abbreviated version of the Beck Depression Inventory-II (BDI-II) that has been previously validated (scale, min=0, max=21, higher mean score indicates more severe depressive symptomology)

Change at 4 months
quality of life
Prazo: Change at 8 months

4-item version of the Lehman Quality of Life Scale (min = 4, max =28, higher score is improved quality of life)

Change at 8 months
quality of life
Prazo: Change at 6 months

4-item version of the Lehman Quality of Life Scale (min = 4, max =28, higher score is improved quality of life)

Change at 6 months
quality of life
Prazo: Change at 4 months

4-item version of the Lehman Quality of Life Scale (min = 4, max =28, higher score is improved quality of life)

Change at 4 months
recovery
Prazo: Change at 8 months

5-item version of the Questionnaire about the Process of Recovery (scale, min=5, max=25, higher mean indicates more perceived recovery)

Change at 8 months
recovery
Prazo: Change at 6 months

5-item version of the Questionnaire about the Process of Recovery (scale, min=5, max=25, higher mean indicates more perceived recovery)

Change at 6 months
recovery
Prazo: Change at 4 months

5-item version of the Questionnaire about the Process of Recovery (scale, min=5, max=25, higher mean indicates more perceived recovery)

Change at 4 months
treatment motivation (intrinsic versus extrinsic)
Prazo: Change at 8 months

Treatment Motivation Questionnaire-Revised (TMQ-R). The Treatment Motivation Questionnaire-Revised is a 25-item self-assessment survey that assesses several elements of treatment motivation, each ranked 1-5. It is not a single scale that results in an overall score. Some items suggest greatest motivation at a 5 and least at a 1, but others suggest greatest motivation at a 1 and least at a 5.

Change at 8 months
treatment motivation (intrinsic versus extrinsic)
Prazo: Change at 6 months

Treatment Motivation Questionnaire-Revised (TMQ-R). The Treatment Motivation Questionnaire-Revised is a 25-item self-assessment survey that assesses several elements of treatment motivation, each ranked 1-5. It is not a single scale that results in an overall score. Some items suggest greatest motivation at a 5 and least at a 1, but others suggest greatest motivation at a 1 and least at a 5.

Change at 6 months
treatment motivation (intrinsic versus extrinsic)
Prazo: Change at 4 months

Treatment Motivation Questionnaire-Revised (TMQ-R). The Treatment Motivation Questionnaire-Revised is a 25-item self-assessment survey that assesses several elements of treatment motivation, each ranked 1-5. It is not a single scale that results in an overall score. Some items suggest greatest motivation at a 5 and least at a 1, but others suggest greatest motivation at a 1 and least at a 5.

Change at 4 months
Perceived coercion
Prazo: Change at 8 months

Modified version of the MacArthur Admission Experience Survey (AES). The MacArthur AES was developed as a self-assessment for assessing coercion and pressure during inpatient admission. It was previously modified for assisted outpatient treatment. We have modified it further to a 13-item scale for outpatient treatment generally. Each item is assessed as true or false, where true suggests great perception of pressure or coercion on some items, but less on others.

Change at 8 months
Perceived coercion
Prazo: Change at 6 months

Modified version of the MacArthur Admission Experience Survey (AES). The MacArthur AES was developed as a self-assessment for assessing coercion and pressure during inpatient admission. It was previously modified for assisted outpatient treatment. We have modified it further to a 13-item scale for outpatient treatment generally. Each item is assessed as true or false, where true suggests great perception of pressure or coercion on some items, but less on others.

Change at 6 months
Perceived coercion
Prazo: Change at 4 months

Modified version of the MacArthur Admission Experience Survey (AES). The MacArthur AES was developed as a self-assessment for assessing coercion and pressure during inpatient admission. It was previously modified for assisted outpatient treatment. We have modified it further to a 13-item scale for outpatient treatment generally. Each item is assessed as true or false, where true suggests great perception of pressure or coercion on some items, but less on others.

Change at 4 months
attendance rate
Prazo: Change over 8 months

number of appointments attended in a given period divided by number of appointments scheduled

Change over 8 months
attendance rate
Prazo: Change at 6 months

number of appointments attended in a given period divided by number of appointments scheduled

Change at 6 months
attendance rate
Prazo: Change at 4 months

number of appointments attended in a given period divided by number of appointments scheduled

Change at 4 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de fevereiro de 2025

Conclusão Primária (Real)

18 de dezembro de 2025

Conclusão do estudo (Estimado)

31 de dezembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

20 de junho de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

28 de julho de 2023

Primeira postagem (Real)

1 de agosto de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

1 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 2023-03

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .